Cargando…

ALK Negative Inflammatory Myofibroblastic Tumor Synchronous with Classical Hodgkin Lymphoma

Inflammatory myofibroblastic tumor or inflammatory pseudotumor was first described by Brunn in 1932. Umiker et al. named it so in 1954 for its ability to mimic malignancy clinically and radiologically [Med Pediatr Oncol 2000; 35(5): 484–7]. This tumor, characterized by its rareness, affects mainly t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sandoval, Letícia, França, Marcos Vinícius, Sanmartino, Daniel, Zattar Piazera, Flávia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477491/ https://www.ncbi.nlm.nih.gov/pubmed/31043949 http://dx.doi.org/10.1159/000495030

Ejemplares similares

Synchronous Nodal Involvement of Metastatic Adenocarcinoma and Classical Hodgkin’s Lymphoma
por: Sachdev, Ritesh, et al.
Publicado: (2017)

ALK negative inflammatory myofibroblastic tumor of the orbit: A masquerading entity
por: Dutta, Vibha, et al.
Publicado: (2014)

Anaplastic Lymphoma Kinase (ALK)-Negative Inflammatory Myofibroblastic Tumor of the Kidney in a Nine-Month-Old Girl
por: Tareen, Bisma, et al.
Publicado: (2022)

The Grey Zones of Classic Hodgkin Lymphoma
por: Bosch-Schips, Jan, et al.
Publicado: (2022)

ALK-negative urachal inflammatory myofibroblastic tumor in an elderly female: A case report
por: Wang, Kai, et al.
Publicado: (2018)

Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation
por: Ogata, Misato, et al.
Publicado: (2018)

Genetics of classical Hodgkin Lymphoma
por: Schiavoni, Gianluca, et al.
Publicado: (2018)

ALK-negative urachal inflammatory myofibroblastic tumor in an elderly female: A case report: Erratum
Publicado: (2019)

ALK 1 Negative Inflammatory Myofibroblastic Tumor of the Ileum: A Rare Cause of Ileocecal Intussusception
por: Yagnik, Vipul D.
Publicado: (2020)

Composite follicular lymphoma and classic Hodgkin lymphoma
por: Kim, Han-Na, et al.
Publicado: (2022)

The molecular mechanisms of classic Hodgkin's lymphoma.
por: Felberbaum, Rachael S.
Publicado: (2005)

Immunological Deregulation in Classic Hodgkin Lymphoma
por: Romano, Alessandra, et al.
Publicado: (2014)

Controversies in the Treatment of Classical Hodgkin Lymphoma
por: Eichenauer, Dennis A., et al.
Publicado: (2018)

Inflammatory microenvironment in classical Hodgkin’s lymphoma with special stress on mast cells
por: Ribatti, Domenico, et al.
Publicado: (2022)

The real risk of secondary non-Hodgkin lymphoma following classical Hodgkin lymphoma
por: Dogan, Ahmet
Publicado: (2022)

Bob-1 is expressed in classic Hodgkin lymphoma
por: Abd El All, Howayda S
Publicado: (2007)

Resources-Stratified Guidelines for Classical Hodgkin Lymphoma
por: Relecom, Allan, et al.
Publicado: (2020)

MicroRNA signature in classical Hodgkin lymphoma
por: Paczkowska, Julia, et al.
Publicado: (2021)

Bone marrow involvement by classic Hodgkin lymphoma
por: Barouqa, Mohammad, et al.
Publicado: (2022)

Aberrant synaptophysin expression in classic Hodgkin lymphoma
por: Im, Soyoung, et al.
Publicado: (2022)

Current directions in the treatment of classical Hodgkin lymphoma
por: Keller, Frank G., et al.
Publicado: (2023)

CAR-T Cell Therapy for Classical Hodgkin Lymphoma
por: Katsin, Mikalai, et al.
Publicado: (2023)

An Unusual Case of Systemic Inflammatory Myofibroblastic Tumor with Successful Treatment with ALK-Inhibitor
por: Jacob, Sanjivini V., et al.
Publicado: (2014)

Case report: Epithelioid inflammatory myofibroblastic sarcoma treated with an ALK TKI ensartinib
por: Li, Mengmeng, et al.
Publicado: (2023)

Remission of ALK-negative primary pulmonary inflammatory myofibroblastic tumor on treatment with clarithromycin: A case report and review of the literature
por: WATANABE, HIDEHIRO, et al.
Publicado: (2016)

Metastatic Anaplastic Lymphoma Kinase-1 (ALK-1)-Rearranged Inflammatory Myofibroblastic Sarcoma to the Brain with Leptomeningeal Involvement: Favorable Response to Serial ALK Inhibitors: A Case Report
por: Yuan, Cai, et al.
Publicado: (2017)

Treatment outcomes in classic Hodgkin lymphoma: 5‐year update from the Brazilian Hodgkin Lymphoma Registry
por: Biasoli, Irene, et al.
Publicado: (2023)

AP-1 family transcription factors: a diverse family of proteins that regulate varied cellular activities in classical hodgkin lymphoma and ALK+ ALCL
por: Wu, Zuoqiao, et al.
Publicado: (2021)

The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future
por: Richardson, S. E., et al.
Publicado: (2011)

Hemophagocytic Lymphohistiocytosis in a Patient with Classical Hodgkin Lymphoma
por: Hyun, G., et al.
Publicado: (2016)

The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma
por: Meti, Nicholas, et al.
Publicado: (2018)

Combined linkage and association analysis of classical Hodgkin lymphoma
por: Lawrie, Alastair, et al.
Publicado: (2018)

Mucocutaneous Paraneoplastic Syndrome Secondary to Classical Hodgkin’s Lymphoma
por: Jurkovic, Jenna, et al.
Publicado: (2019)

Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
por: Voorhees, Timothy J, et al.
Publicado: (2020)

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
por: Lai, Catherine, et al.
Publicado: (2019)

Classical Hodgkin’s Lymphoma in the Era of Immune Checkpoint Inhibition
por: De Re, Valli, et al.
Publicado: (2019)

Cell-Free DNA for the Management of Classical Hodgkin Lymphoma
por: Camus, Vincent, et al.
Publicado: (2021)

Classical Hodgkin Lymphoma Presenting as a Sigmoid Mass
por: Caulkins, Heather, et al.
Publicado: (2021)

Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma
por: Tarekegn, Kidist, et al.
Publicado: (2021)

Optimization of the first line treatment in classical Hodgkin's lymphoma
por: Brice, Pauline
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bbru8f1p7ci9ku5986ti872put